Comerica Bank Buys New Position in Evolus, Inc. (NASDAQ:EOLS)

Comerica Bank bought a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 28,301 shares of the company's stock, valued at approximately $312,000.

Other hedge funds also recently made changes to their positions in the company. KBC Group NV bought a new position in shares of Evolus during the fourth quarter worth about $49,000. IFP Advisors Inc raised its position in shares of Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after acquiring an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Evolus during the fourth quarter worth about $106,000. Quantbot Technologies LP bought a new position in shares of Evolus during the fourth quarter worth about $118,000. Finally, Tradition Wealth Management LLC raised its position in shares of Evolus by 18.2% during the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after acquiring an additional 2,000 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Barclays lifted their target price on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a report on Thursday, May 8th. Finally, BTIG Research started coverage on Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $23.75.

Insiders Place Their Bets

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares in the company, valued at $418,057.17. The trade was a 28.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the sale, the insider now owns 362,467 shares of the company's stock, valued at approximately $4,806,312.42. This represents a 7.15% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 86,241 shares of company stock worth $1,048,666. 5.90% of the stock is owned by corporate insiders.

Evolus Trading Down 0.3%

EOLS stock traded down $0.03 during mid-day trading on Thursday, reaching $9.56. The company's stock had a trading volume of 690,193 shares, compared to its average volume of 692,495. The company has a market cap of $616.39 million, a price-to-earnings ratio of -10.51 and a beta of 1.11. The business's 50 day moving average price is $11.04 and its 200 day moving average price is $12.18. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.